Co-Authors
This is a "connection" page, showing publications co-authored by Dario Cattaneo and Massimo Galli.
Connection Strength
1.488
-
Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. J Med Virol. 2021 03; 93(3):1421-1427.
Score: 0.226
-
Does lopinavir really inhibit SARS-CoV-2? Pharmacol Res. 2020 08; 158:104898.
Score: 0.220
-
Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice. World J Biol Psychiatry. 2020 10; 21(8):651-657.
Score: 0.197
-
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. J Acquir Immune Defic Syndr. 2018 01 01; 77(1):86-92.
Score: 0.187
-
Generics for the Treatment of Hepatitis C in Monoinfected and HIV-coinfected Patients: Pros and Cons. AIDS Rev. 2017 Oct-Dec; 19(3):167-172.
Score: 0.184
-
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Antivir Ther. 2017; 22(4):353-356.
Score: 0.174
-
Consumption of antibiotics at an Italian university hospital during the early months of the COVID-19 pandemic: Were all antibiotic prescriptions appropriate? Pharmacol Res. 2021 02; 164:105403.
Score: 0.058
-
Drug-induced liver steatosis in patients with HIV infection. Pharmacol Res. 2019 07; 145:104267.
Score: 0.051
-
Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. BMC Infect Dis. 2018 Nov 12; 18(1):556.
Score: 0.050
-
Clinical and genetic determinants of nevirapine plasma trough concentration. SAGE Open Med. 2018; 6:2050312118780861.
Score: 0.048
-
Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial. New Microbiol. 2018 Apr; 41(2):106-111.
Score: 0.047
-
Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors. Drug Metab Pers Ther. 2017 05 24; 32(2):115-117.
Score: 0.045